Prognostic value of PCSK9 levels in patients with acute coronary syndromes.
Eur Heart J. 2016.
PMID: 26655339
Clinical Trial.
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Search Results
2 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
Prognostic value of PCSK9 levels in patients with acute coronary syndromes.
Gencer B, Montecucco F, Nanchen D, Carbone F, Klingenberg R, Vuilleumier N, Aghlmandi S, Heg D, Räber L, Auer R, Jüni P, Windecker S, Lüscher TF, Matter CM, Rodondi N, Mach F.
Gencer B, et al.
Eur Heart J. 2016 Feb 7;37(6):546-53. doi: 10.1093/eurheartj/ehv637. Epub 2015 Dec 9.
Eur Heart J. 2016.
PMID: 26655339
Free article.
Clinical Trial.
We aimed to prospectively assess the prognostic value of plasma PCSK9 levels in patients with acute coronary syndromes (ACS). METHODS AND RESULTS: Plasma PCSK9 levels were measured in 2030 ACS patients u …
We aimed to prospectively assess the prognostic value of plasma PCSK9 levels in patients with acute …
Item in Clipboard
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, Ruhaak LR, Schwertfeger M, Tsimikas S, White HD, Steg PG, Cobbaert C, Schwartz GG; ODYSSEY OUTCOMES Investigators.
Szarek M, et al.
Circulation. 2024 Jan 16;149(3):192-203. doi: 10.1161/CIRCULATIONAHA.123.066398. Epub 2023 Aug 26.
Circulation. 2024.
PMID: 37632469
Free PMC article.
METHODS: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the PCSK9 inhibitor alirocumab with placebo in patients with recent acute coronary …
METHODS: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Trea …
Item in Clipboard
Cite
Cite